Pfizer is asking the Food and Drug Administration to authorize its COVID-19 booster shots for all adults. Booster shots are currently only authorized for elderly and at-risk individuals. (CNBC Weekly)

The Oklahoma Supreme Court rejected a ruling that would require Johnson & Johnson to pay the state $465 million for its role in the opioid epidemic. The court threw out the state’s argument that J&J violated “public nuisance” laws by overplaying the benefits of prescription opioids. (The New York Times)

In the largest randomized trial of the psychedelic to date, Psilocybin showed to be effective in treating depression. Patients given the highest dose of 25 milligrams experienced a significant reduction in depression symptoms compared to patients given one milligram. (STAT)

Biogen is investigating the death of a patient who experienced brain swelling after taking its Alzheimer’s drug Aduhelm. “We continue to work with the reporting physicians as well as the global regulators to further understand the case,” the company said in a statement. (Reuters)

Arbor Biotechnologies, a spinout from Feng Zhang’s MIT CRISPR lab, announced it has received $215 million in Series B funding. The biotech will use the funding to develop new therapies from CRISPR-based gene editing tools. (Endpoints News)